Verona Pharma plc - American Depositary Share (VRNA) News

Verona Pharma plc - American Depositary Share (VRNA): $4.30

0.11 (+2.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter VRNA News Items

VRNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VRNA News Highlights

  • VRNA's 30 day story count now stands at 5.
  • Over the past 14 days, the trend for VRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest VRNA News From Around the Web

Below are the latest news stories about Verona Pharma plc that investors may wish to consider to help them evaluate VRNA as an investment opportunity.

Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

GlobeNewswire | February 17, 2022

Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster

Verona Pharma (VRNA) was founded in 2005 and is based in London, U.K. The company’s lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease, COPD (after tiotropium). The advantage of dual PDE3 and PDE4 inhibition...

Bhavneesh Sharma on Seeking Alpha | February 4, 2022

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

Top-line Data Expected in the Third Quarter of 2022LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-2 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). Top-line data are expect

Yahoo | January 24, 2022

Verona Pharma (VRNA) Gets a Buy Rating from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $25.00. The company's shares closed last Wednesday at $6.88. According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of -4.5% and a 33.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verona Pharma with a $21.60 average price target, representing a 206.4% upside. In a report issued on January 3, H.C.

Christine Brown on TipRanks | January 6, 2022

Analysts Offer Insights on Healthcare Companies: Spectrum Pharmaceuticals (SPPI), Sensus Healthcare (SRTS) and Verona Pharma (VRNA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spectrum Pharmaceuticals (SPPI – Research Report), Sensus Healthcare (SRTS – Research Report) and Verona Pharma (VRNA – Research Report) with bullish sentiments. Spectrum Pharmaceuticals (SPPI) In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Spectrum Pharmaceuticals, with a price target of $10.00. The company's shares closed last Wednesday at $1.27. According to TipRanks.com, White is a 4-star analyst with an average return of -22.1% and a 20.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.

Christine Brown on TipRanks | January 6, 2022

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022 LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces enrollment completed in the 48-week subset of the ENHANCE-1 trial in December 2021. The ENHANCE-2 trial has completed screening with 788 subjects

Yahoo | January 5, 2022

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand starting at 7:00 AM EST / 12:00 PM GMT on Monday, January 10, 2022. A webcast of the event will b

Yahoo | January 4, 2022

Verona Pharma (VRNA) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $25.00. The company's shares closed last Friday at $6.72. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Verona Pharma has an analyst consensus of Strong Buy, with a price target consensus of $21.60, which is a 209.9% upside from current levels.

Christine Brown on TipRanks | January 3, 2022

2 “Strong Buy” Penny Stocks That Can Deliver Over 200% Gains Next Year

Every class of stocks has its promoters and detractors, but few generate such extreme opinions among investors as the penny stocks. The reality is, they’re a class of assets that offer some unique opportunities combined with a higher risk profile.  The ‘pennies’ are stocks selling at ultra-low prices per share. Originally, they were priced for just a few pennies, but today this class of stocks is generally valued at less than $5 per share. Such low share prices generally happen for clear reasons, and those reasons usually revolve around something fundamentally wrong with the issuing company. But not always.

Michael Marcus on TipRanks | December 16, 2021

Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction

Study Supports Ongoing Phase 3 Program and Planned NDA SubmissionLONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces ensifentrine met all safety objectives in a thorough QT (“TQT”) study designed to evaluate effects, if any, of ensifentrine on cardiac conduction in healthy individuals. No clinically relevant changes in measures of cardiac conduct

Yahoo | December 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4618 seconds.